FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma

por Kasamon, Yvette L., de Claro, R. Angelo, Wang, Yaping, Shen, Yuan Li, Farrell, Ann T., Pazdur, Richard
Publicado 2017

FDA Approval Summary: Vemurafenib for the Treatment of Patients with Erdheim‐Chester Disease with the BRAFV600 Mutation

por Oneal, Patricia A., Kwitkowski, Virginia, Luo, Lola, Shen, Yuan Li, Subramaniam, Sriram, Shord, Stacy, Goldberg, Kirsten B., McKee, Amy E., Kaminskas, Edvardas, Farrell, Ann, Pazdur, Richard
Publicado 2018

Analysis of racial and ethnic disparities in multiple myeloma US FDA drug approval trials

por Kanapuru, Bindu, Fernandes, Laura L., Fashoyin-Aje, Lola A., Baines, Andrea C., Bhatnagar, Vishal, Ershler, Rachel, Gwise, Thomas, Kluetz, Paul, Pazdur, Richard, Pulte, Elizabeth, Shen, Yuan-Li, Gormley, Nicole
Publicado 2022

FDA Approval Summary: Daratumumab for Treatment of Multiple Myeloma After One Prior Therapy

por Bhatnagar, Vishal, Gormley, Nicole J., Luo, Lola, Shen, Yuan Li, Sridhara, Rajeshwari, Subramaniam, Sriram, Shen, Guoxiang, Ma, Lian, Shord, Stacy, Goldberg, Kirsten B., Farrell, Ann T., McKee, Amy E., Pazdur, Richard
Publicado 2017

Exploring racial disparities in treatment patterns and outcomes for patients with multiple myeloma using real world data

por Maignan, Kathleen, Fashoyin-Aje, Lola A., Torres, Aracelis Z., Fernandes, Laura L., Gwise, Thomas, Baxi, Shrujal B., Roose, James P., Rivera, Donna R., Shen, Yuan Li, Kluetz, Paul G., Gormley, Nicole J.
Publicado 2022